PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …

Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two
binding domains targeting B cell maturation antigen. Our previous reports showed a …

Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …

Background: Multiple myeloma (MM) is a hematological malignancy characterized by the
exponential growth of malignant plasma cells. Individuals diagnosed with MM exhibit a …

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation
developed after administration of chimeric antigen receptor (CAR) T-cell therapy with …

Outcomes are poor in triple-class–exposed (TCE) relapsed and refractory multiple myeloma
(R/RMM). In the phase 3 KarMMa-3 trial, patients with TCE R/RMM and 2 to 4 prior regimens …

Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma,
was approved in USA on 28 February 2022, for patients with relapsed or refractory disease …

Simple Summary Multiple myeloma (MM) is the second most common hematological
malignancy with median age of diagnosis between 65–70 years. Since the introduction of …

Multiple myeloma (MM) affects~ 500,000 people and results in~ 100,000 deaths annually,
being currently considered treatable but incurable. There are several MM chemotherapy …

Acetylation is a reversible post-translational modification (PTM) that regulates important
cellular processes such as proliferation, DNA damage repair and cell cycle progress. When …